Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors

Introduction: Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the real world. Methods: To evaluate the association bet...

Full description

Bibliographic Details
Main Authors: Ryo Ariyasu, MD, Sho Kakuto, MD, Keiki Miyadera, MD, Takahiro Akita, MD, Ayu Kiritani, MD, Ryosuke Tsugitomi, MD, Yoshiaki Amino, MD, Ken Uchibori, MD, PhD, Satoru Kitazono, MD, PhD, Noriko Yanagitani, MD, PhD, Makoto Nishio, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
Long-term survival data
Real-world
A tyrosine kinase inhibitor
Immune checkpoint inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323000632

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323000632

Similar Items